Skip to main content
Reviews Epitalon

The eye studies and the wider Epithalon record

Amounts and routes

Epithalon dosage records

An amount is meaningful only with the subject and route attached. These are records of experiments, with no established general human regimen.

The retinal series: study amounts

The 2002 retinitis pigmentosa series reported 5.0 micrograms by parabulbar injection, near the eye, for 10 consecutive days. Its 162 participants had a specific retinal disease. That local route is central to the context.

The amount loses its context as soon as it travels away from that paper. It cannot supply a general anti-aging regimen or establish the safety of a different route. Controlled human evidence for a standard Epithalon dose remains absent.

Epithalon protocol in mice

The 2003 female SHR mouse study used 1.0 microgram per mouse by subcutaneous injection on 5 consecutive days per month, beginning at age 3 months and continuing until death. The 2006 C3H/He tumor study used 0.1 microgram, 5 times per week.

These are different experiments with different endpoints. A schedule observed in a mouse study has no validated conversion into a personal cycle. I would need human pharmacokinetics and controlled safety results before treating any frequency as established for people.

Concentrations around cells

In the 2025 telomere study, cancer cell lines were exposed to 0.1, 0.2, 0.5 or 1 microgram per milliliter for 4 days; normal cells received 1 microgram per milliliter for 3 weeks. The retinal-cell wound experiment used 20, 40 or 60 nanograms per milliliter.

A concentration in culture medium describes the liquid immediately surrounding isolated cells. There is no stomach, circulation or whole-body distribution in that exposure. The precision of these figures is useful for repeating the laboratory work; repeating it is the purpose for which I trust these figures.

A laboratory pipette suspended over a clear multiwell culture plate on an ivory bench
Editorial still life of cell-culture equipment. Concentrations in culture medium describe an experiment, rather than an amount established for human care.

Routes studied

Rodent experiments used injections beneath the skin. The human retinal series used a route near the eye. The fruit-fly lifespan study exposed developing flies through their culture medium, while the human cell-line experiment added Epitalon directly to the surrounding liquid.

Published human bioavailability measurements for oral or sublingual Epitalon are lacking in this record. Small molecular size alone cannot establish how much reaches the blood. The 2025 review leaves practical pharmacokinetic questions open.

Promise Peptides offers prescription peptide care at mypromise.com, with its licensed U.S. clinician deciding whether to prescribe after assessing each person. The study amounts and forms still do not set a personal care plan.

Epitalon half-life

No formal human pharmacokinetic half-life study has established how quickly Epitalon disappears from blood. The review of the peptide’s properties leaves that gap unresolved. Half-life describes the time for a concentration to fall by half.

I’d enter “unmeasured” in that space. A guess borrowed from other short peptides cannot fill it. Clearance from blood and the duration of a downstream gene-expression change are different measurements. Neither a mouse calendar nor a cell-culture exposure supplies those missing human data.